SUNPHARMA Q1 FY27 results at a glance
SUN PHARMACEUTICAL IND L Q1 FY27 key results metrics| Quarter | Q1 FY27 |
|---|
| Quarter ended | 30 Jun 2026 |
|---|
| Revenue | ₹15,184 cr |
|---|
| Revenue YoY | +10.1% |
|---|
| Operating profit | ₹3,557 cr |
|---|
| Operating margin | 23.4% |
|---|
| Net profit | ₹2,895 cr |
|---|
| Net profit YoY | +27.0% |
|---|
| Net profit QoQ | +6.7% |
|---|
| Net margin | 19.1% |
|---|
| Basic EPS | ₹12.10 |
|---|
| TTM revenue | ₹58,998 cr |
|---|
| TTM net profit | ₹11,256 cr |
|---|
| TTM net margin | 19.1% |
|---|
SUNPHARMA Q1 FY27 results: what the numbers say
SUN PHARMACEUTICAL IND L (SUNPHARMA) has reported its Q1 FY27 results for the quarter ended 2026-06-30. The company posted revenue of ₹15,184 cr and a net profit of ₹2,895 cr, translating into earnings per share of ₹12.10.
Compared with the same quarter a year earlier, revenue grew by +10.1% and net profit grew strongly by +27.0%. Profit rising faster than revenue points to better cost control or operating leverage flowing through the P&L.
Operating profit for the quarter stood at ₹3,557 cr, an operating margin of 23.4% versus 24.5% a year ago — a contraction of 1.0 percentage points.
SUNPHARMA quarter-wise results table
Revenue
₹15,184 cr
+10.1% YoY
Net profit
₹2,895 cr
+27.0% YoY
Operating profit
₹3,557 cr
+5.5% YoY
SUN PHARMACEUTICAL IND L (SUNPHARMA) quarter-wise results — revenue, operating profit, net profit, margins, EPS and growth| Quarter | Revenue | Operating profit | Net profit | OPM | Net margin | EPS | Profit YoY | Profit QoQ |
|---|
| Q1 FY272026-06-30 | ₹15,184 cr | ₹3,557 cr | ₹2,895 cr | 23.4% | 19.1% | ₹12.10 | +27.0% | +6.7% |
| Q4 FY262026-03-31 | ₹14,560 cr | ₹2,752 cr | ₹2,714 cr | 18.9% | 18.6% | ₹11.30 | +26.2% | -19.4% |
| Q3 FY262025-12-31 | ₹15,469 cr | ₹4,062 cr | ₹3,369 cr | 26.3% | 21.8% | ₹14.00 | — | +47.8% |
| Q1 FY262025-06-30 | ₹13,786 cr | ₹3,372 cr | ₹2,279 cr | 24.5% | 16.5% | ₹9.50 | — | +6.0% |
| Q4 FY252025-03-31 | ₹12,816 cr | ₹2,761 cr | ₹2,150 cr | 21.5% | 16.8% | ₹9.00 | — | — |
| TTM (last 4 quarters) | ₹58,998 cr | ₹13,743 cr | ₹11,256 cr | 23.3% | 19.1% | ₹46.90 | — | — |
Consolidated figures as reported to the exchanges, shown in ₹ crore. OPM = operating profit margin. Updated automatically whenever a new quarter is filed.
SUNPHARMA quarterly income statement
Line-item results for the last six quarters as filed — sales, expenses, operating profit, interest, tax and profit after tax in ₹ crore.
SUN PHARMACEUTICAL IND L quarterly income statement| Particulars | Q1 FY272026-06-30 | Q4 FY262026-03-31 | Q3 FY262025-12-31 | Q1 FY262025-06-30 | Q4 FY252025-03-31 |
|---|
| Revenue / Sales | ₹15,184 cr | ₹14,560 cr | ₹15,469 cr | ₹13,786 cr | ₹12,816 cr |
|---|
| Total expenses | ₹11,627 cr | ₹11,808 cr | ₹11,407 cr | ₹10,414 cr | ₹10,055 cr |
|---|
| Gross profit | ₹12,220 cr | ₹11,759 cr | ₹12,524 cr | ₹10,971 cr | ₹10,178 cr |
|---|
| Operating profit (EBIT) | ₹3,557 cr | ₹2,752 cr | ₹4,062 cr | ₹3,372 cr | ₹2,761 cr |
|---|
| Operating margin | 23.4% | 18.9% | 26.3% | 24.5% | 21.5% |
|---|
| Interest cost | ₹99.67 cr | ₹85.89 cr | ₹78.36 cr | ₹74.8 cr | ₹49.14 cr |
|---|
| Profit before tax | ₹4,099 cr | ₹3,551 cr | ₹4,227 cr | ₹3,173 cr | ₹3,254 cr |
|---|
| Tax expense | ₹1,188 cr | ₹828 cr | ₹826 cr | ₹870 cr | ₹1,094 cr |
|---|
| Effective tax rate | 29.0% | 23.3% | 19.5% | 27.4% | 33.6% |
|---|
| Net profit (PAT) | ₹2,895 cr | ₹2,714 cr | ₹3,369 cr | ₹2,279 cr | ₹2,150 cr |
|---|
| Net profit margin | 19.1% | 18.6% | 21.8% | 16.5% | 16.8% |
|---|
| Basic EPS | ₹12.10 | ₹11.30 | ₹14.00 | ₹9.50 | ₹9.00 |
|---|
| Diluted EPS | ₹12.10 | ₹11.30 | ₹14.00 | ₹9.50 | ₹9.00 |
|---|
SUNPHARMA results growth — YoY and QoQ
Quarterly growth rates, year on year and quarter on quarter| Growth | Q1 FY27 | Q4 FY26 | Q3 FY26 | Q1 FY26 | Q4 FY25 |
|---|
| Revenue YoY | +10.1% | +13.6% | — | — | — |
|---|
| Revenue QoQ | +4.3% | -5.9% | +12.2% | +7.6% | — |
|---|
| Operating profit YoY | +5.5% | -0.3% | — | — | — |
|---|
| Operating profit QoQ | +29.3% | -32.3% | +20.5% | +22.1% | — |
|---|
| Net profit YoY | +27.0% | +26.2% | — | — | — |
|---|
| Net profit QoQ | +6.7% | -19.4% | +47.8% | +6.0% | — |
|---|
| EPS YoY | +27.4% | +25.6% | — | — | — |
|---|
| EPS QoQ | +7.1% | -19.3% | +47.4% | +5.6% | — |
|---|
SUNPHARMA annual results history
Full-year performance for SUN PHARMACEUTICAL IND L, useful for reading each quarter in context.
SUN PHARMACEUTICAL IND L annual income statement| Particulars | FY262026-03-31 | FY252025-03-31 | FY242024-03-31 | FY232023-03-31 |
|---|
| Revenue / Sales | ₹58,220 cr | ₹52,041 cr | ₹47,758 cr | ₹43,279 cr |
|---|
| Total expenses | ₹44,625 cr | ₹39,460 cr | ₹37,290 cr | ₹34,002 cr |
|---|
| Gross profit | ₹45,047 cr | ₹39,844 cr | ₹35,689 cr | ₹31,336 cr |
|---|
| Operating profit (EBIT) | ₹13,595 cr | ₹12,581 cr | ₹10,468 cr | ₹9,277 cr |
|---|
| Operating margin | 23.4% | 24.2% | 21.9% | 21.4% |
|---|
| Interest cost | ₹339 cr | ₹231 cr | ₹238 cr | ₹172 cr |
|---|
| Profit before tax | ₹15,119 cr | ₹13,752 cr | ₹11,088 cr | ₹9,408 cr |
|---|
| Tax expense | ₹3,554 cr | ₹2,772 cr | ₹1,439 cr | ₹848 cr |
|---|
| Effective tax rate | 23.5% | 20.2% | 13.0% | 9.0% |
|---|
| Net profit (PAT) | ₹11,479 cr | ₹10,929 cr | ₹9,576 cr | ₹8,474 cr |
|---|
| Net profit margin | 19.7% | 21.0% | 20.1% | 19.6% |
|---|
| Basic EPS | ₹47.80 | ₹45.60 | ₹39.90 | ₹35.30 |
|---|
| Diluted EPS | ₹47.80 | ₹45.60 | ₹39.90 | ₹35.30 |
|---|
Revenue trend and demand read-through
Topline for Q1 FY27 came in at ₹15,184 cr against ₹13,786 cr in Q1 FY26, and ₹14,560 cr in the preceding Q4 FY26 quarter.
On a sequential basis revenue grew +4.3%. Sequential moves are the quickest read on demand momentum because they strip out the base effect of a year-old quarter, though seasonality can distort a single quarter.
Total expenses for the quarter were ₹11,627 cr, or 76.6% of revenue, with operating profit grew +5.5% year on year.
Margins, tax and profitability
Net profit of ₹2,895 cr works out to a net margin of 19.1% compared with 16.5% in the year-ago quarter. Margin expansion of this kind usually reflects a better product or service mix, softer input costs, or tighter overheads.
Below the operating line, SUN PHARMACEUTICAL IND L reported profit before tax of ₹4,099 cr, a tax charge of ₹1,188 cr (effective rate 29.0%), interest cost of ₹99.67 cr. Reading these together with operating profit shows how much of the quarter's earnings were driven by the core business versus financing and tax movements.
Sequentially, net profit moved from ₹2,714 cr in Q4 FY26 to ₹2,895 cr in Q1 FY27, a change of +6.7%.
Trailing twelve months and annual context
Across the trailing four quarters SUN PHARMACEUTICAL IND L has generated revenue of ₹58,998 cr and net profit of ₹11,256 cr, a trailing net margin of 19.1%. The trailing view smooths out one-off quarters and is the number most valuation multiples are built on.
On a full-year basis, FY26 revenue was ₹58,220 cr with net profit of ₹11,479 cr and EPS of ₹47.80, versus the prior year where revenue grew +11.9% and profit grew +5.0%.
What to watch in the next SUNPHARMA quarter
For the coming quarters the numbers worth tracking on this page are revenue momentum, the operating margin trend, the interest burden and whether EPS keeps pace with profit growth. A sustained run of year-on-year profit growth is what usually drives a re-rating rather than any single quarter.
SUN PHARMACEUTICAL IND L has not yet intimated its next results date to the exchange. This page refreshes automatically from filings and the board-meeting calendar, so the tables above will reflect the next quarter as soon as it is reported.
All figures here are as reported to the exchanges and shown in ₹ crore, without adjustment. This is information and analysis, not investment advice.
SUNPHARMA results coverage
No results report published for SUNPHARMA yet — our desk covers each quarter within minutes of the filing.
SUNPHARMA quarterly results FAQs
What were SUN PHARMACEUTICAL IND L (SUNPHARMA) Q1 FY27 results?
In Q1 FY27 (quarter ended 30 Jun 2026), SUN PHARMACEUTICAL IND L reported revenue of ₹15,184 cr and net profit of ₹2,895 cr, a change of +27.0% year on year on +10.1% revenue growth. EPS stood at ₹12.10.
What is SUNPHARMA profit margin in Q1 FY27?
SUN PHARMACEUTICAL IND L posted a net profit margin of 19.1% and an operating margin of 23.4% in Q1 FY27. On a trailing twelve-month basis, revenue is ₹58,998 cr and net profit ₹11,256 cr.
Did SUNPHARMA results beat the previous quarter?
SUN PHARMACEUTICAL IND L net profit changed +6.7% quarter on quarter, from ₹2,714 cr in Q4 FY26 to ₹2,895 cr in Q1 FY27.
When are SUN PHARMACEUTICAL IND L (SUNPHARMA) quarterly results?
SUN PHARMACEUTICAL IND L has not yet intimated its next results date to the exchange. This page updates automatically from the exchange board-meeting calendar.
Where can I see SUNPHARMA latest quarterly results?
Results coverage for SUNPHARMA will appear here as soon as the company reports. Meanwhile you can track live price and technicals on the SUNPHARMA stock page.
What is SUN PHARMACEUTICAL IND L annual revenue and profit?
For FY26, SUN PHARMACEUTICAL IND L reported full-year revenue of ₹58,220 cr and net profit of ₹11,479 cr, with EPS of ₹47.80.
How many quarterly results has SUNPHARMA declared recently?
Past results dates for SUNPHARMA will be listed here from the exchange calendar.
Results dates sourced from the exchange board-meeting calendar; reported figures from company filings, last refreshed 11 Sept 2026. For information only, not investment advice.
